Elan faces a "kick-back" probe from the US Department of Justice and the Department of Health, new filings have revealed, leaving the firm open to "substantial fines" if found guilty.
The investigation into Elan involves the promotion of its anti convulsant Zonegran , which it sold to rival pharma group Eisai almost three years ago. Filings note that the investigation relates to "anti kick-back and false claims laws".
Source
No comments:
Post a Comment